Literature DB >> 25634611

Dissecting complement blockade for clinic use.

Antonio M Risitano1.   

Abstract

In this issue of Blood, Peffault de Latour et al describe ex vivo measurements of complement activity in paroxysmal nocturnal hemoglobinuria (PNH) patients on eculizumab treatment. This is the first systematic pharmacodynamic (PD) study of eculizumab in PNH patients which shows that CH50 is a promising biomarker of therapeutic complement blockade.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25634611     DOI： 10.1182/blood-2014-12-616300

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.

Authors:  Antonio M Risitano; Serena Marotta; Patrizia Ricci; Luana Marano; Camilla Frieri; Fabiana Cacace; Michela Sica; Austin Kulasekararaj; Rodrigo T Calado; Phillip Scheinberg; Rosario Notaro; Regis Peffault de Latour
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 2.  Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.

Authors:  Raymond S M Wong
Journal:  Ther Adv Hematol       Date:  2022-07-28

3.  Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue.

Authors:  Kelly C Fahnoe; Fei Liu; Jennifer G Morgan; Sarah T Ryan; Michael Storek; Ellen Garber Stark; Fred R Taylor; V Michael Holers; Joshua M Thurman; Stefan Wawersik; Susan L Kalled; Shelia M Violette
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

4.  The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation.

Authors:  Samuel Antwi-Baffour; Ransford Kyeremeh; Jonathan Kofi Adjei; Claudia Aryeh; George Kpentey
Journal:  Auto Immun Highlights       Date:  2016-03-03

5.  Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.

Authors:  Markus J Harder; Britta Höchsmann; Arthur Dopler; Markus Anliker; Christof Weinstock; Arne Skerra; Thomas Simmet; Hubert Schrezenmeier; Christoph Q Schmidt
Journal:  Front Immunol       Date:  2019-07-18       Impact factor: 7.561

Review 6.  How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.

Authors:  Antonio Maria Risitano; Régis Peffault de Latour
Journal:  Br J Haematol       Date:  2021-08-05       Impact factor: 8.615
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.